Juno Therapeutics
4
71M
2
0.40
1
0.50
2
- Areas of investment
Summary
In 2013 was created Juno Therapeutics, which is appeared as Corporate Investor. The main department of described Corporate Investor is located in the Seattle. The venture was found in North America in United States.
The fund is constantly included in less than 2 investment rounds annually. The usual things for fund are deals in the range of 50 - 100 millions dollars. The top amount of exits for fund were in 2016. The top activity for fund was in 2018.
The fund has no exact preference in some founders of portfolio startups. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight JW Therapeutics, Editas Medicine. Among the most successful fund investment fields, there are Therapeutics, Genetics. Besides, a startup needs to be aged 2-3 years to get the investment from the fund.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Juno Therapeutics, startups are often financed by Third Rock Ventures, Polaris Partners, Partners Innovation Fund. The meaningful sponsors for the fund in investment in the same round are YuanMing Capital, WuXi AppTec, Temasek Holdings. In the next rounds fund is usually obtained by Viking Global Investors, Third Rock Ventures, T. Rowe Price.
The current fund was established by Isabelle Riviu00e8re, Michael Jensen, Michel Sadelain, Phil Greenberg, Renier Brentjens, Stan Riddell.
Investments analytics
Analytics
- Total investments
- 4
- Lead investments
- 1
- Exits
- 2
- Rounds per year
- 0.40
- Follow on index
- 0.50
- Investments by industry
- Health Care (4)
- Biotechnology (4)
- Medical (2)
- Genetics (2)
- Therapeutics (2)
- Investments by region
-
- China (2)
- United States (2)
- Peak activity year
- 2015
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Avg. valuation at time of investment
- 450M
- Group Appearance index
- 0.50
- Strategy success index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| JW Therapeutics | 11 Jun 2020 | Biotechnology, Health Care, Therapeutics | Early Stage Venture | 100M | Shanghai, China |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.